湖南思为康医药

Hunan Siweikang Therapeutics is a clinical-stage Chinese biotechnology company founded in 2018 by Dr. Biliang Hu, a former postdoctoral researcher under CAR-T pioneer Dr. Carl June. The company is dedicated to the development and localization of chimeric antigen receptor T-cell (CAR-T) therapies, leveraging its proprietary SAFET platform to design safer, multi-targeted cell therapies. Its lead clinical programs include SWK001 (SCAR-02), a dual-targeting BCMA-CD19 CAR-T cell therapy being evaluated for multiple myeloma and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In addition to therapeutic development, Siweikang has co-founded Truking Siweikang (楚天思为康) in partnership with Truking Technology to develop automated, closed-system cell manufacturing equipment, aiming to significantly reduce the production costs of cell therapies.